Takeda Pharmaceutical Company and NuBiyota are partnering to exploit the latter's Microbial Ecosystem Therapeutic platform for developing therapeutic oral microbial consortia products for gastroenterology indications. Under terms of the agreement, NuBiyota will receive an undisclosed up-front payment and will be eligible for future development, regulatory, and commercial milestones, plus tiered sales royalties. Financial details were not disclosed.

NuBiyota terms its Microbial Ecosystem Therapeutic as a clinic-ready microbial consortia for use as a starting point in evaluating microbiome based-therapeutics and provding new insights into the roles of microbiota in gastrointestinal diseases. “We are excited to partner with NuBiyota, as this collaboration reinforces Takeda’s long-term commitment to unmet medical need in gastroenterology and adds to our other microbiome-related partnerships,” said Asit Parikh, M.D., Ph.D., head of Takeda’s gastroenterology therapeutic area unit. “Through these partnerships, we are exploring both microbial consortia and microbiome-derived bioactives to investigate how the microbiome can be harnessed for treatment of GI diseases.”

The collaboration with Nubiyota represents Takeda’s second microbiome deal this month. Just last week, the firm reported a global collaboration with Finch Therapeutics to develop a preclinical-stage microbiome therapeutic for inflammatory bowel disease. Takeda expanded its gastrointestinal diseases pipeline in January through a deal with PvP Biologics to develop an enzyme therapy for treating the effects of gluten ingestion by patients with celiac disease.

Takeda completed its $5.2 billion acquisition of Ariad Pharmaceuticals in mid February.